Acrisure Capital Management’s Humana HUM Stock Holding History

Acrisure Capital Management’s Portfolio HUM Stock Details HUM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-998	Closed	-$484K	–	108
2023 Q1	$484K	Sell	998 -145	-13%	-$71.7K	0.49%	54
2022 Q4	$585K	Buy	+1,143	New	+$601K	0.65%	33

Other funds holding HUM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Acrisure Capital Management's HUM Position: Q2 2023 in Review

Acrisure Capital Management sold out of Humana (HUM) in Q2 2023, closing a stake of 998 shares — an estimated $484K sold.

Acrisure Capital Management first reported a position in HUM in Q4 2022 and held it in 2 quarters. The position peaked at $585K in Q4 2022. 1,071 funds tracked by Wall St. Rank hold HUM as of Q2 2023.

Acrisure Capital Management reported no remaining Humana position as of Q2 2023 after selling out during the quarter.
Acrisure Capital Management sold 998 Humana shares in Q2 2023, an estimated $484K.
Acrisure Capital Management first reported a position in Humana in Q4 2022 and held it in 2 quarters.
Acrisure Capital Management's Humana position peaked at $585K in Q4 2022.
1,071 funds tracked by Wall St. Rank held Humana as of Q2 2023.

Based on Acrisure Capital Management's 13F filing for Q2 2023.